LIVE DAY 3 ✦ September 25 - CT (Central Time)
LIVE DAY 3 ✦ September 25 - CT (Central Time)
Improving the math for holistic view on value and negotiation leverage with CMS and PDABs
Revaluating modeling to avoid undercounting value in certain therapies and products based on quantifiable values
- Peter Rubin - Executive Director, No Patient Left Behind
Hear from an expert panel of attorneys as they each moderate a topic and interactive discussion among attendees and themselves, on the most pressing issues facing MDRP and Government Pricing.
- Tom Evegan - Principal, Strategy & Management Consulting, RSM US LLP
- Jeffrey Handwerker - Partner, Arnold & Porter LLP
- Hear from Medicare and payers on their perspective on this new program:
Smoothing program – also being called the Medicare prescription payment program - is going to allow patients that opt into Medicare to pay monthly
Process: Plans will pay upfront and collection in the back end
Possible impact on industry stakeholders
What manufacturers can do to prepare their patients
- Mallory O’Connor - Executive Director, Public Policy, Mallinckrodt Pharmaceuticals
- The industry as a whole has been interrupted with new, fast-paced models and technology:
Moving towards value-based care and solutions
How technology has changed the industry and current exceptional practices
Moving away from the traditional
What new models and companies are on the front of change?
CMS rare disease and cell and gene therapies
- The industry needs to be fully serialized by November 2024 with the ability to track each and every vial of product. Explore new technology that tracks shipment and use (and reuse) of product.
How are manufacturers planning to meet the expectations and obligations of serialization?
Product protection and response to diversion
The history driving counterfeit concerns
- Roneil Narciso - Director Strategic Pricing & Contracting, AVEO Oncology
- State level forecasting and implications
Understanding implementation and the future of PDABs and UPLs
Access, reimbursement, copay, affordability considerations
How to manage each individual state and retain accuracy of the data
Create tools for success in organization, documentation, and staying informed
Operationalize new technology and build infrastructure around SOPs
Work directly with states on clarification for language and properly document their responses
- Elizabeth Lindquist - Partner, Arnold & Porter
Join this highly engaging and interactive anonymous live polling to benchmark with your peers on their SPTR and PDAB challenges and responses, SOPs, and more. Come ready with your smartphone to participate!
Join this summit of Senior Executives from across Pharma to participate in facilitated, interactive, and innovative discussions on some of the areas below, to drive results back at your organization. Limited to 35 participants:
340B litigation
RFI by CMS for vendor
PBM reform
State level trends and activity
IRA implementation concerns
Technology innovation
Smoothing
Stacking
Drug shortage
Serialization
GTN
- J'Amie Conrod, MSPH - Senior Director, Government Payor Engagement, U.S. Market Access, Amgen
- Katheryne Richardson, PharmD - Executive Director and Head US 340B Strategy, Bristol Myers Squibb
- James Kelly - Director, Medicaid, Novartis
Hear from gene therapy company on their huge innovation in high-cost gene therapy approvals in various states for value-based agreements and SRAs:
How to decide if a VBA or SRA is right for your product
Market access for your product
Working with states to formalize and employ
How to implement VBAs within MDRP